Clinical Trial Update: Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing Empagliflozin/Linagliptin/Metformin HCl Extended-Release Tablets to Trijardy XR Extended-Release Tablets in adults with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin/Linagliptin/Metformin HCl Extended-Release Tablets (empagliflozin/linagliptin/metformin hydrochloride extended-release)
• Trijardy XR Extended Release Film Coated Tablets (empagliflozin; linagliptin; metformin hydrochloride extended-release)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Status: COMPLETED